Batch selection based on CDP [Dissolution / BCS / IVIVC]

posted by dshah  – India/United Kingdom, 2022-03-02 20:17 (463 d 20:32 ago) – Posting: # 22819
Views: 711

Dear BE proff!
I believe there is no specific answer for your question. If drug is belonging to BCS class I/III- kindly follow the BCS based biowaiver guideline but for BCS II/IV- multiple factors can play a role.
The Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action by EMA can be useful for the choice in selecting media (emphasis on discrimination).
But the biorelvence can only be confirmed after the study outcome. F2 criteria alone are many times not useful.
The PIL can be useful for time point selection to capturing ADME but many times the Tmax, t1/2 can be slightly different in the research article.
Regards,
Divyen Shah

Complete thread:

UA Flag
Activity
 Admin contact
22,627 posts in 4,743 threads, 1,613 registered users;
25 visitors (0 registered, 25 guests [including 9 identified bots]).
Forum time: 17:50 CEST (Europe/Vienna)

Facts are meaningless. You could use facts to prove
anything that’s even remotely true!    Homer Simpson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5